CMS Bundling Ruling Neutral for DaVita, Says Piper Jaffray (DVA)

Piper Jaffray analysts Mark Arnold and Bradley Fisher weighed in on the CMS' ruling for bundled dialysis services.

The analysts said, "In total, the only real change to the average estimated bundled payment is the exclusion of certain oral drugs until 2014. Pending further commentary from the company, we maintain our Neutral rating and continue to view the implementation of bundling as a neutral event for DVA."

DaVita is rated Neutral by Piper Jaffray, with a price target of $66.

Shares of DVA are currently trading at $60.86.